Compounds and methods for the inhibition of the expression...

Details Compounds and methods for the inhibition of the expression... Compounds and methods for the inhibition of the expression...

2007-03-13

2007-03-13

Oh, Taylor Victor (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acid esters

C560S142000

Reexamination Certificate

active

10647766

ABSTRACT:
This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

REFERENCES:
patent: 3179701 (1965-04-01), Rocklin
patent: 3479407 (1969-11-01), Laufer
patent: 3576883 (1971-04-01), Neuworth
patent: 3952064 (1976-04-01), Whalley
patent: 4029812 (1977-06-01), Wagner
patent: 4076841 (1978-02-01), Wagner
patent: 4078084 (1978-03-01), Wagner
patent: 4115590 (1978-09-01), Lerner
patent: 4752616 (1988-06-01), Hall
patent: 4755524 (1988-07-01), Mueller et al.
patent: 4954514 (1990-09-01), Kita
patent: 4968710 (1990-11-01), Rustad
patent: 4975467 (1990-12-01), Ku et al.
patent: 5043330 (1991-08-01), Nguyen et al.
patent: 5061734 (1991-10-01), Mao et al.
patent: 5066822 (1991-11-01), Rustad et al.
patent: 5084214 (1992-01-01), Kita et al.
patent: 5112870 (1992-05-01), Mao et al.
patent: 5155250 (1992-10-01), Parker
patent: 5206247 (1993-04-01), Regnier
patent: 5262439 (1993-11-01), Parthasarathy
patent: 5294724 (1994-03-01), Jendralla et al.
patent: 5310949 (1994-05-01), Dufresne et al.
patent: 5380747 (1995-01-01), Medford
patent: 5411741 (1995-05-01), Zaias
patent: 5512595 (1996-04-01), Regnier et al.
patent: 5608095 (1997-03-01), Parker
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5693337 (1997-12-01), Suzuki et al.
patent: 5739374 (1998-04-01), Janssen et al.
patent: 5750351 (1998-05-01), Medford
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5783596 (1998-07-01), Medford et al.
patent: 5792787 (1998-08-01), Medford et al.
patent: 5807884 (1998-09-01), Medford et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5821260 (1998-10-01), Medford et al.
patent: 5846959 (1998-12-01), Medford et al.
patent: 6037377 (2000-03-01), Anderskewitz et al.
patent: 6121319 (2000-09-01), Somers
patent: 6147250 (2000-11-01), Somers
patent: 6323359 (2001-11-01), Jass
patent: 6548699 (2003-04-01), Somers
patent: 6602914 (2003-08-01), Meng
patent: 6617352 (2003-09-01), Somers
patent: 6670398 (2003-12-01), Edwards et al.
patent: 2002/0188118 (2002-12-01), Meng
patent: 2002/0193446 (2002-12-01), Meng
patent: 2003/0064967 (2003-04-01), Luchoomun et al.
patent: 27 16 125 (1977-10-01), None
patent: 0190682 (1986-08-01), None
patent: 0254272 (1988-01-01), None
patent: 0292660 (1988-11-01), None
patent: 0317165 (1989-05-01), None
patent: 0348203 (1989-12-01), None
patent: 0405788 (1991-01-01), None
patent: 0418648 (1991-03-01), None
patent: 0621255 (1994-10-01), None
patent: 0763527 (1997-03-01), None
patent: 0866049 (1998-09-01), None
patent: 2130975 (1972-11-01), None
patent: 2133024 (1972-11-01), None
patent: 2134810 (1972-12-01), None
patent: 2140769 (1973-01-01), None
patent: 2140771 (1973-01-01), None
patent: 2168137 (1973-08-01), None
patent: 1136539 (1968-12-01), None
patent: 1148550 (1969-04-01), None
patent: 1199871 (1970-07-01), None
patent: 49-075552 (1974-07-01), None
patent: 06-312978 (1994-11-01), None
patent: 73-28425 (1995-12-01), None
patent: 09-059258 (1997-03-01), None
patent: WO 93/02051 (1993-02-01), None
patent: WO 94/07869 (1994-04-01), None
patent: WO 95/09158 (1995-04-01), None
patent: WO 95/15760 (1995-06-01), None
patent: WO 95/17408 (1995-06-01), None
patent: WO 95/30415 (1995-11-01), None
patent: WO 96/12703 (1996-05-01), None
patent: WO 97/15546 (1997-05-01), None
patent: WO 97/26258 (1997-07-01), None
patent: WO 97/48694 (1997-12-01), None
patent: WO 98/22418 (1998-05-01), None
patent: WO 99/24400 (1998-05-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 98/51662 (1998-11-01), None
patent: WO 99/15159 (1999-04-01), None
patent: WO 00/26167 (2000-05-01), None
patent: WO 00/26184 (2000-05-01), None
patent: WO 00/28332 (2000-05-01), None
patent: WO 00/31053 (2000-06-01), None
patent: WO 00/59509 (2000-10-01), None
patent: WO 01/70757 (2001-09-01), None
patent: WO 01/70757 (2001-09-01), None
patent: WO 01/79164 (2001-10-01), None
patent: WO 01/79164 (2001-10-01), None
Anonymous, “AtheroGenics announces positive Phase II results from CART-1 Clinical Trial for restenosis,” (Press Release Nov. 12, 2001).
Anonymous, “AtheroGenics: Faster than anticipated,”BioCentury Extra(The Bernstein Report of Biobusiness), Reprint from May 29, 2001.
Barnhart, J.W., et al., Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs,Pharmacochem. Libr., 1991(17):277-299 (1991). XP002095165.
Baron, J.L., et al., “The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between α-4-integrins and vascular cell adhesion molecule-1”,J. Clin. Invest. 93:1700-1708 (Apr. 1994).
Brown, et al., “Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis”,Ann. Rev. Biochem., 52:223-261 (1983).
Burkly, L.C., et al., “Protection against adoptive transfer of autoimmune diabletes mediated through very late antigen-4 integrin”,Diabetes, 43:529-534 (Apr. 1994).
Carew, et al., “Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidantsin vivocan selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit”,Proc. Natl. Acad. Sci. U.S.A., 84:7725-7729 (Nov. 1987).
Cominacini, L., et al.,Free Radical Biology and Medicine, 22(1/2):117-127 (1996) XP002095164.
De Meglio, P., “New derivatives of clofibrate and probucol. Preliminary studies on hypolipemic activity,”Il Farmaco, Ed. Sci. 40(11):833-844 (1985).With partial translation. Chem. Abstracts, 104(5):28675, (Feb. 3, 1986), XP 002124424.
Feldman, D., et al., “The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881,”Atherosclerosis, 144:343-355 (Dec. 28, 1998).
Folkman, J., et al., “Angiogenesis”,J. Biol. Chem., 267(16):10931-10934 (Jun. 5, 1992).
Fruebis, J., “A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits,”The American Society for Clinical Investigation, Inc., 94:392-398 (Jul. 1994).
Gershbein et al., “Action of drugs and chemical agents on rat liver regeneration,”Drug and Chemical Toxicology, 8(3):125-143 (1985).
Heeg, et al., “Plasma levels of Procubol in man after single and repeated oral doses”,La Nouvelle Presse Medicale, 9(40):2990-2994 (Oct. 30, 1980).Abstract in English.
Iademarco, M.F., et al., “Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1)”,J. Biol. Chem. 267(23):16323-16329 (Aug. 15, 1992).
Kazuya et al.,J. Lipid Res., 32:197-204 (1991).
Kelarev, V.I., et al.,Khim. Geterotsikl. Soedin, No. 5, pp. 667-673 (1995). Provided asChem. Abstracts, AN 124:146082, XP002115604.
Kelarev, V.I., et al.,Khim. Geterotsikl. Soedin., No. 4, pp. 514-517 (1995). Provided asChem. AbstractsAN 124(1):8690 (Jan. 1, 1996) XP002115603 and XP002115596.
Koch, A.E., et al., “Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues”,Lab. Invest., 64(3):313-320 (1991).
Lankin, V.Z., et al.,Dokl. Akad. Nauk., 351(4):554-557 (1996),Chem. Abstracts, AN 127(6):75973u (1997), XP002115597.
Mamedov, Ch.I., et al.,Mater. Nauchn. Konf. Aspir. Akad. Nauk Az. SSR, 1:127-131 (1980),Chem. Abstracts, AN 94:30290c (1981), XP002115600.
Mao., S.J., et al., “Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic watanabe Rabbits,”Journal of Medicinal Chemistry, 34(1):298-302 (Jan. 1991).
Mao, S.J., et al., “Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits with Use of a Probucol Analogues (MDL29,311) That Does Not Lower serum Cholesterol,”Arteriosclerosis and Thrombosis. 11(5):1266-1275 (Sep.-O

Affiliated with

Also associated with

Rating

Compounds and methods for the inhibition of the expression... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and methods for the inhibition of the expression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the inhibition of the expression... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3768717